Minireviews
Copyright ©The Author(s) 2020.
World J Clin Cases. Aug 26, 2020; 8(16): 3411-3430
Published online Aug 26, 2020. doi: 10.12998/wjcc.v8.i16.3411
Figure 3
Figure 3 Immune checkpoint inhibitor-related acute pancreatitis in a patient receiving pembrolizumab for malignant melanoma. A and B: Positron emission tomography-computed tomography and simple abdominal computed tomography at start of pembrolizumab showing normal pancreas and Peri pancreatic tissue (arrows); C and D: Positron emission tomography-computed tomography and simple abdominal computed tomography images 2 mo after starting pembrolizumab, showing increased activity at the tail of the pancreas (max SUV 8.2), Peri pancreatic fat stranding and Peri pancreatic fluid at the body and tail of pancreas (arrows).